Mira Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapies for CNS, metabolic, and pain disorders. Its lead program, Ketamir-2, has an active IND and is in Phase 1 for chemotherapy-induced neuropathic pain, with a Phase 2a planned in the first half of this year. The pipeline also includes SKNY-1 for smoking cessation and weight loss and MIRA-55 for inflammatory pain.